Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$816.65 USD

816.65
879,559

-12.78 (-1.54%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $816.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off

by Zacks Equity Research

J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.

Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies

by Zacks Equity Research

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

by Zacks Equity Research

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna

by Zacks Equity Research

Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.

Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More

by Zacks Equity Research

Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.

Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?

by Zacks Equity Research

Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

by Zacks Equity Research

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

by Zacks Equity Research

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management

by Zacks Equity Research

Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Amazon.com, Boeing, Regeneron & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).

Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the Invesco Biotechnology & Genome (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD

by Zacks Equity Research

Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.

Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate

by Zacks Equity Research

Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca

by Zacks Equity Research

Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.

Sanghamitra Saha headshot

Oncology Market's Huge Potential Puts These Stocks in Focus

by Sanghamitra Saha

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

by Zacks Equity Research

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.

Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug

by Kinjel Shah

FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.

Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News

by Zacks Equity Research

Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.

Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies

by Zacks Equity Research

Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.

Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered

by Zacks Equity Research

Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.